Stock Analysis on Net

Cigna Group (NYSE:CI)

Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Cigna Group, consolidated balance sheet: liabilities and stockholders’ equity

US$ in millions

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Current insurance and contractholder liabilities 5,514 5,385 5,318 5,308 4,921
Pharmacy and other service costs payable 19,815 17,070 15,309 13,347 10,454
Accounts payable 8,553 7,775 6,655 5,478 5,090
Accrued expenses and other liabilities 9,955 8,006 7,322 8,515 7,347
Short-term debt 2,775 2,993 2,545 3,374 5,514
Liabilities of businesses held for sale 2,104 6,423 6,812
Current liabilities 48,716 41,229 43,572 36,022 40,138
Non-current insurance and contractholder liabilities 10,904 11,481 12,563 16,844 16,052
Deferred tax liabilities, net 7,173 7,751 8,346 8,939 9,387
Other non-current liabilities 3,441 3,142 3,762 4,629 4,460
Long-term debt 28,155 28,100 31,125 29,545 31,893
Separate account liabilities 7,430 7,278 8,337 9,086 8,465
Liabilities of businesses held for sale, non-current 591
Non-current liabilities 57,694 57,752 64,133 69,043 70,257
Total liabilities 106,410 98,981 107,705 105,065 110,395
Redeemable noncontrolling interests 107 66 54 58 35
Common stock, $0.01 par value per share 4 4 4 4 4
Additional paid-in capital 30,669 30,233 29,574 28,975 28,306
Accumulated other comprehensive loss (1,864) (1,395) (884) (861) (941)
Retained earnings 41,652 37,874 32,593 28,575 20,162
Treasury stock, at cost (24,238) (21,844) (14,175) (6,372) (2,193)
Shareholders’ equity 46,223 44,872 47,112 50,321 45,338
Other noncontrolling interests 21 13 18 7 6
Total equity 46,244 44,885 47,130 50,328 45,344
Total liabilities and equity 152,761 143,932 154,889 155,451 155,774

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Cigna Group current liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level.
Non-current liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Cigna Group non-current liabilities decreased from 2021 to 2022 and from 2022 to 2023.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Cigna Group total liabilities decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.
Shareholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Cigna Group shareholders’ equity decreased from 2021 to 2022 but then increased from 2022 to 2023 not reaching 2021 level.